Investing.com — Novo Nordisk (NYSE:) shares fell 2% following the release of STEP UP Obesity Study results. The results showed that semaglutide 7.2 mg achieved weight loss of 20.7% in participants and 18.7% regardless of treatment compliance. .
The Danish drug company reported that its 72-week Phase 3B trial met its primary endpoint, with 7.2 mg of semaglutide showing significant weight loss compared to placebo. In this study of 1,407 obese adults, 33.2% of patients receiving semaglutide 7.2 mg experienced a weight loss of 25% or more, compared with 16.7% with semaglutide 2.4 mg and none with placebo. It also became clear that
Despite these results, Novo Nordisk’s share price declined. This may reflect investor concerns about the commercial impact and regulatory outlook of new doses. Study results also showed that the most common adverse events were gastrointestinal disturbances typical of the GLP-1 receptor agonist class, and were mostly mild to moderate in severity.
Martin Horst Lange, Executive Vice President of Development at Novo Nordisk, expressed satisfaction with the trial results, highlighting the significant weight loss and patient outcomes with high doses of semaglutide. He noted that the results support the drug’s profile and established health benefits for obesity treatment, including the reduced cardiovascular risk seen with the currently available Wegovy® (semaglutide 2.4 mg). did.
The company plans to present detailed results from the STEP UP study at a scientific conference in 2025, and in the coming months will begin a Phase 2 and 3 study of semaglutide 7.2 mg in adults with type 2 diabetes and obesity. Waiting for results.
Wegovy® is already available for weight management in adults and certain pediatric patients in the EU and US, and is being added to reduce the risk of serious cardiovascular events (MACE) in adults with established cardiovascular disease. It also has adaptations.
Novo Nordisk’s share price decline may reflect current market uncertainty as investors make sense of the trial results and look forward to more data from the upcoming STEP UP T2D trial There is.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
